A federal consultative group voted Thursday to ease rules on seven peptides, including BPC-157 and TB-500. The vote was close. It is not binding. The FDA has given no word on whether it will take up the recommendation. The move came after weeks of public hearings. Wellness backers lobbied intensely for wider access. RFK Jr. was among them. Critics say these compounds have insufficient safety data or help for most uses. The call could redefine how the agency handles a part of the wellness market that is surging ahead. Market observers are watching to see if the agency adopts the plan. A spokesperson for the regulator offered no fixed date for a next move. Wellness voices argue the change would open up access to compounds people say help them. Health groups warn that looser rules could invite misuse across a fast-scaling market. The Thursday vote only opens the door to a change, and the final call rests with the regulator.